John Lapré to fulfill role as Elekta’s Chief Technology Officer

STOCKHOLM, April 20, 2016 – In order to further strengthen its innovation leadership, Elekta (EKTA-B.ST) announced today the appointment of John Lapré as Chief Technology Officer, effective May 1, 2016.

John Lapré says: “The CTO responsibilities are to stimulate growth through innovation and to further raise customer satisfaction with the clinical effectiveness of Elekta’s portfolio.”

Tomas Puusepp, President and CEO, says the role demonstrates the company’s continued commitment to advancing health care and improving outcomes for patients. He says: “John Lapré will be an ideal CTO. In addition to intimately knowing the company and our industry, he has a keen understanding of collaboration and innovation, which are key elements for our customers and their patients.”

John Lapré previously held the title of Executive Vice President Research and Innovation at Elekta. Prior to this, he was Executive Vice President Brachytherapy and before joining Elekta in 2011, John was Vice President R&D at Nucletron.

John Lapré received his MSc and PhD in Toxicology & Nutrition in the Netherlands, majoring in intestinal physiology, toxicology and biochemistry. His PhD focused on the prevention of colorectal cancer.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on April 20, 2016.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.

Tags:

About Us

Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,700 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com

Subscribe

Documents & Links